PTC Therapeutics (PTCT) to Announce Quarterly Earnings on Thursday

PTC Therapeutics (NASDAQ:PTCT) is expected to issue its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect PTC Therapeutics to announce earnings of $0.22 per share and revenue of $298.6320 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.42. The business had revenue of $272.55 million for the quarter, compared to the consensus estimate of $217.42 million. PTC Therapeutics had a negative net margin of 22.58% and a negative return on equity of 362.45%. The business’s revenue for the quarter was up 43.5% on a year-over-year basis. During the same period in the prior year, the firm earned $10.04 EPS. On average, analysts expect PTC Therapeutics to post $0 EPS for the current fiscal year and $2 EPS for the next fiscal year.

PTC Therapeutics Stock Down 1.3%

Shares of NASDAQ:PTCT traded down $0.99 during midday trading on Wednesday, reaching $74.39. The company’s stock had a trading volume of 88,947 shares, compared to its average volume of 1,452,361. The stock has a fifty day moving average of $77.40 and a 200 day moving average of $72.81. PTC Therapeutics has a twelve month low of $43.17 and a twelve month high of $90.87. The firm has a market capitalization of $6.17 billion, a PE ratio of -31.91, a P/E/G ratio of 6.60 and a beta of 0.53.

Insiders Place Their Bets

In other PTC Therapeutics news, CEO Matthew B. Klein sold 12,572 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $72.95, for a total value of $917,127.40. Following the sale, the chief executive officer directly owned 393,998 shares of the company’s stock, valued at approximately $28,742,154.10. This trade represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Christine Marie Utter sold 19,686 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $75.56, for a total value of $1,487,474.16. Following the completion of the sale, the chief accounting officer owned 70,199 shares of the company’s stock, valued at $5,304,236.44. This trade represents a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 198,662 shares of company stock valued at $16,347,994. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On PTC Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. UMB Bank n.a. purchased a new stake in PTC Therapeutics in the 4th quarter worth $26,000. Comerica Bank lifted its holdings in PTC Therapeutics by 868.5% during the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 469 shares in the last quarter. IFP Advisors Inc lifted its holdings in PTC Therapeutics by 68.1% during the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 310 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of PTC Therapeutics by 247.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 814 shares during the period. Finally, Smartleaf Asset Management LLC grew its position in shares of PTC Therapeutics by 96.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 921 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 452 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Royal Bank Of Canada upped their price target on shares of PTC Therapeutics from $82.00 to $85.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Wells Fargo & Company reduced their price objective on PTC Therapeutics from $95.00 to $93.00 and set an “overweight” rating for the company in a research note on Monday, July 20th. Morgan Stanley reissued an “overweight” rating and issued a $94.00 price objective on shares of PTC Therapeutics in a report on Friday, May 8th. Jefferies Financial Group upgraded PTC Therapeutics from a “hold” rating to a “buy” rating and upped their target price for the stock from $76.00 to $85.00 in a research note on Wednesday, May 27th. Finally, Citigroup raised PTC Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $75.00 to $108.00 in a report on Tuesday, June 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, PTC Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $93.83.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.